Literature DB >> 16815454

Clinical laboratories, the select agent program, and biological surety (biosurety).

Ross H Pastel1, Gretchen Demmin, Grant Severson, Rafael Torres-Cruz, Jorge Trevino, John Kelly, Jay Arrison, Joy Christman.   

Abstract

The threat of bioterrorism has led to increased concerns over the availability of biological select agents and toxins (BSAT). Congress has implemented several public laws that have led to the development of federal regulations by the Centers for Disease Control and Prevention (CDC) and the US Department of Agriculture. The CDC regulation 42 CFR 73 has a direct impact on all clinical laboratories that may at some time identify BSAT in a clinical specimen. The Department of Defense has imposed a more stringent layer of regulation called biological surety (biosurety) on top of the requirements of 42 CFR 73 for military laboratories that possess BSAT. However,42 CFR 73 falls into the framework of biosurety. Both sets of regulations have four pillars (safety, physical security, agent account-ability, and personnel reliability) that are built on a foundation of training and covered by a roof of management (operations and plans).

Mesh:

Substances:

Year:  2006        PMID: 16815454     DOI: 10.1016/j.cll.2006.03.004

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  7 in total

1.  Select agent and toxin regulations: beyond the eighth edition of the Guide for the Care and Use of Laboratory Animals.

Authors:  Robin J Kastenmayer; Rashida M Moore; Allison L Bright; Rafael Torres-Cruz; William R Elkins
Journal:  J Am Assoc Lab Anim Sci       Date:  2012-05       Impact factor: 1.232

Review 2.  The Culture of Biosafety, Biosecurity, and Responsible Conduct in the Life Sciences: A Comprehensive Literature Review.

Authors:  Dana Perkins; Kathleen Danskin; A Elise Rowe; Alicia A Livinski
Journal:  Appl Biosaf       Date:  2019-03-01

3.  Double-stranded RNA-activated protein kinase mediates induction of interleukin-8 expression by deoxynivalenol, Shiga toxin 1, and ricin in monocytes.

Authors:  Jennifer S Gray; Hee Kyong Bae; James C B Li; Allan S Lau; James J Pestka
Journal:  Toxicol Sci       Date:  2008-07-03       Impact factor: 4.849

4.  ABSL-4 aerobiology biosafety and technology at the NIH/NIAID integrated research facility at Fort Detrick.

Authors:  Matthew G Lackemeyer; Fabian de Kok-Mercado; Jiro Wada; Laura Bollinger; Jason Kindrachuk; Victoria Wahl-Jensen; Jens H Kuhn; Peter B Jahrling
Journal:  Viruses       Date:  2014-01-07       Impact factor: 5.048

Review 5.  Pathogen security-help or hindrance?

Authors:  Stephen A Morse
Journal:  Front Bioeng Biotechnol       Date:  2015-01-06

Review 6.  Emerging and zoonotic infections in women.

Authors:  Regan N Theiler; Sonja A Rasmussen; Tracee A Treadwell; Denise J Jamieson
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

Review 7.  The impact of regulations, safety considerations and physical limitations on research progress at maximum biocontainment.

Authors:  Amy C Shurtleff; Nicole Garza; Matthew Lackemeyer; Ricardo Carrion; Anthony Griffiths; Jean Patterson; Samuel S Edwin; Sina Bavari
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.